Predictive biomarkers for immunotherapy in non-small cell lung cancer

Predictive biomarkers for immunotherapy in non-small cell lung cancer

User Photo
EMJ

4 years
564 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses immunotherapy as an option for patients with non-small cell lung cancer (NSCLC) who progress after initial treatment, as well as programmed death-ligand 1 (PD-L1) expression as a predictive biomarker for the development of immunotherapy.



European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay